Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
uniQure NVLTS:0EE0 +1.44%43 Receivables Turnover is 0.76 as of Mar. 2026. GuruFocus rates LTS:0EE0 with a GF Score™ of 43/100 and a GF Value™ of $6.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 840 Biotechnology companies, uniQure NV ranks worse than 61.43% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. uniQure NV's Revenue for the
three
months ended in Mar. 2026 was $3.56 Mil. uniQure NV's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4.71 Mil.
Hence, uniQure NV's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.76.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
uniQure NV Receivables Turnover Related Terms
uniQure NV Receivables Turnover Historical Data
* Premium members only.
The historical data trend for uniQure NV's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0EE0 vs ATAI, RARE, CLDX: Receivables Turnover Comparison
For the Biotechnology subindustry, uniQure NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where uniQure NV's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (LTS:0EE0) has a Receivables Turnover of 0.76 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #516 out of 840 companies in the Biotechnology industry, placing it in the top 61.4%.
Is uniQure NV's Receivables Turnover too high?
uniQure NV's current Receivables Turnover is 0.76. The Biotechnology industry median Receivables Turnover is 5.28. uniQure NV's value of 0.76 is 85.6% below this industry median. Based on the distribution chart, uniQure NV ranks #516 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, uniQure NV has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Receivables Turnover compare to ATAI and RARE?
According to the Biotechnology industry distribution chart, uniQure NV ranks #516 out of 840 companies for Receivables Turnover. This places uniQure NV in the lower half of its industry. The industry median Receivables Turnover is 5.28. uniQure NV's value of 0.76 is 85.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Receivables Turnover of 0.76 is 85.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Receivables Turnover is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.20, compared to a current price of $38.78 — trading 525.5% above its estimated fair value. The current Receivables Turnover is 0.76 and 85.6% below the Biotechnology industry median of 5.28. uniQure NV's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current Receivables Turnover is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (LTS:0EE0) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $38.78 is trading 525.5% above its estimated GF Value™ of $6.20.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for LTS:0EE0:
Receivables Turnover: 0.76
GF Value™: $6.20 vs. price of $38.78 (525.5% above fair value)
Industry Position: 85.6% below the Biotechnology median (#516 of 840)
No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
43GF Score
Get the complete analysis for LTS:0EE0
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0EE0 has been successfully added to your 
